Canine splenic hemangiosarcoma (HSA) is an aggressive tumour of vascular endothelium that carries a grave prognosis following standard of care treatment with surgery and doxorubicin. A previous pilot study revealed potential anti-tumour activity of I'm-Yunity polysaccharopeptide (PSP) for canine...
Author(s)
Gedney, A.; Salah, P.; Mahoney, J. A.; Krick, E.; Martins, R.; Scavello, H.; Lenz, J. A.; Atherton, M. J.
Publisher
Wiley, Oxford, UK
Citation
Veterinary and Comparative Oncology, 2022, 20, 3, pp 688-696
Background: Both human and veterinary cancer chemotherapy are undergoing a paradigm shift from a "one size fits all" approach to more personalized, patient-oriented treatment strategies. Personalized chemotherapy is dependent on the identification and validation of biomarkers that can predict...
Author(s)
Walters, K.; Stornetta, A.; Jacobs, F.; Villalta, P. W.; Razzoli, M.; Grant, M.; Zordoky, B.; Bartolomucci, A.; Borgatti, A.; Balbo, S.
Publisher
BioMed Central Ltd, London, UK
Citation
BMC Veterinary Research, 2021, 17, 378, pp (7 December 2021)
Opioid receptor activation was shown to enhance the efficacy of anti-neoplastic drugs in several human cancer cell lines. In these cell lines, doxorubicin increased the number of opioid receptors and methadone concurrently enhanced cellular doxorubicin uptake. Triggered through lay press and media, ...
Author(s)
Cueni, C.; Nytko, K. J.; Thumser-Henner, P.; Weyland, M. S.; Bley, C. R.
Publisher
Wiley, Oxford, UK
Citation
Veterinary Medicine and Science, 2020, 6, 3, pp 283-289
Topoisomerase IIα (TOPIIα) plays a key role in DNA replication and is a molecular target for TOPIIα inhibitor chemotherapy. A doxorubicin-based chemotherapy remains the most effective treatment for canine lymphoma, but there are no clear indications for its use in individual patients. The aim of...
Author(s)
Klimiuk, P.; Łopuszyński, W.; Bulak, K.
Publisher
Polskie Towarzystwo Nauk Weterynaryjnych, Lublin, Poland
Citation
Medycyna Weterynaryjna, 2022, 78, 6, pp 297-303
Canine lymphoma is one of the most common malignant tumours occurring in dogs and has a high incidence worldwide. Despite advances in cancer prevention, the treatment of neoplastic diseases still requires improvement. Some cancer cells may resist the effect of chemotherapeutic agents by...
Author(s)
Chen, W.; Liu, I.; Tomiyasu, H.; Lee, J.; Cheng, C.; Liao, A. T.; Liu, B.; Liu, C.; Lin, C.
Publisher
Elsevier Ltd, Oxford, UK
Citation
Veterinary Journal, 2019, 254, pp 105398
Verdinexor (KPT-335) is a novel orally bioavailable selective inhibitor of nuclear export (SINE) compound that inhibits the function of the nuclear export protein Exportin 1 (XPO1/CRM1). In the present study, we sought to characterize the expression of XPO1 in primary canine osteosarcoma (OS)...
Author(s)
Breitbach, J. T.; Louke, D. S.; Tobin, S. J.; Watts, M. R.; Davies, A. E.; Fenger, J. M.
Publisher
Wiley, Oxford, UK
Citation
Veterinary and Comparative Oncology, 2021, 19, 2, pp 362-373
The aim of this pilot study was to evaluate the cardioprotective effects of carvedilol in dogs receiving doxorubicin chemotherapy and provide suggestions to future studies based on results and limitations of our study. Thirteen dogs were randomized into two experimental groups: 6 dogs in carvedilol ...
Author(s)
Pino, E. H. M.; Weber, M. N.; Oliveira, L. O. de; Vieira, L. C.; Santos, K. H. S. dos; Liu, I. P.; Gomes, H. M.; Trindade-Gerardi, A. B.; Moreira, J. C. F.; Gerardi, D. G.
Publisher
Elsevier Ltd, Oxford, UK
Citation
Research in Veterinary Science, 2021, 135, pp 532-541
Canine mammary gland tumour (CMT) commonly affects the female dog. The objective of this study was to develop a doxorubicin-resistant CMT cell line and determine its in vitro and in vivo characteristics, including mRNA and microRNA (miRNA) expression profiles. Doxorubicin-resistant CMT-Star cells...
Author(s)
Sahabi, K.; Selvarajah, G. T.; Mokrish, A.; Rasedee, A.; Kqueen, C. Y.
Publisher
Taylor & Francis, Abingdon, UK
Citation
Journal of Applied Animal Research, 2022, 50, 1, pp 125-145
Background: Chemotherapy-induced alopecia (CIA) is common in humans, but there are limited reports describing the clinical features of CIA in dogs. Objectives: To describe the epidemiological and clinical characteristics of doxorubicin-associated alopecia (DAA) in canine patients at a teaching...
Author(s)
Falk, E. F.; Lam, A. T. H.; Barber, L. G.; Ferrer, L.
Publisher
Wiley, Oxford, UK
Citation
Veterinary Dermatology, 2017, 28, 2, pp e48
Canine hemangiosarcoma (HSA) is an aggressive malignant endothelial tumor in dogs and characterized by poor prognosis because of its high invasiveness, high metastatic potential, and poor responsiveness to anti-cancer drugs. Although doxorubicin-based chemotherapy is regularly conducted after...
Author(s)
Morita, A.; Aoshima, K.; Gulay, K. C. M.; Onishi, S.; Shibata, Y.; Yasui, H.; Kobayashi, A.; Kimura, T.
Publisher
Elsevier Ltd, Oxford, UK
Citation
Research in Veterinary Science, 2019, 127, pp 1-10